Mikhail Blagosklonny
| Mikhail Blagosklonny | |
|---|---|
| Fields | Anti-aging medicine, oncology |
| Institutions | Roswell Park Cancer Institute |
| Alma mater | First Pavlov State Medical University of St. Peterburg |
Mikhail Blagosklonny is a scientist who studies cancer and aging. He is a professor of oncology at the Roswell Park Cancer Institute in New York.[1]
Career
Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Peterburg.[1] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009 when he was appointed professor of oncology at Roswell Park Cancer Institute.[1]
Blogosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[1]
Rapamycin and aging
Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[2] He is considered one of the most passionate advocates for rapamycin in longevity research.[3]
Editorial activities
Blagosklonny is editor-in-chief of Aging,[4] Cell Cycle,[5] and Oncotarget.[6] In addition, he is associate editor of Cancer Biology & Therapy[7] and a member of the editorial board of Cell Death & Differentiation.[8]
The reviewing process employed by Oncotarget has been criticized by Jeffrey Beall,[9] who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[10] in July 2015.[9]
Selected publications
Blagosklonny has published over 270 papers in peer-reviewed journals with over 25,000 citations, giving him an h-index of 83.[11]
- Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Nature Cell Death & Disease. 2013 Dec 12;4:e964 PMID 24336084
- Leontieva OV, Demidenko ZN, Blagosklonny MV Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. PNAS 2014 Jun 17;111(24):8832-7 PMID 24889617
- Blagosklonny MV. Hypoxia, MTOR and autophagy: converging on senescence or quiescence. Autophagy. 2013 Feb 1;9(2):260-2. PMID 23192222
- Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. PNAS 2012 Aug 14;109(33):13314-8. PMID 22847439
- Leontieva OV, Demidenko ZN, Gudkov AV, Blagosklonny MV. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One 2011;6(10):e26126 PMID 22022534
- Demidenko ZN, Fojo T, Blagosklonny MV. Complementation of two mutant p53: implications for loss of heterozygosity in cancer. FEBS Letters 2005 Apr 11;579(10):2231-5. PMID 15811347
- Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discovery Today 2003 Dec 15;8(24):1104-7 PMID 14678733
- Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF, Fojo T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. PNAS PMID 12145320
- Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature Reviews Cancer PMID 11990858
- Blagosklonny MV. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Nature Leukemia 2002 Apr;16(4):570-2. PMID 11960334
- Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Nature Leukemia 2002 Apr;16(4):455-62. PMID 11960322
- Blagosklonny MV. Pardee AB. Conceptual biology: unearthing the gems. Nature 2002 Mar 28;416(6879):373 PMID 11919607
- Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Nature Leukemia 2001 Oct;15(10):1537-43. PMID 11587211
- Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Nature Leukemia 2001 Jun;15(6):936-41. PMID 11417480
- Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Nature Leukemia 2001 Jun;15(6):869-74. PMID 11417471
References
- 1 2 3 4 Roswell Park Cancer Center Mikhail Blagosklonny profile Page accessed November 30, 2016
- ↑ "A New Path to Longevity". Scientific American. 2011. Retrieved 2016-11-20.
- ↑ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
- ↑ "Editorial Board". Aging. Retrieved 2016-11-20.
- ↑ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
- ↑ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
- ↑ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
- ↑ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
- 1 2 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. WordPress.com. Retrieved 2016-11-20.
- ↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. WordPress.com. Retrieved 19 April 2016.
- ↑ "Mikhail Blagosklonny". Google Scholar. Google. Retrieved 2016-11-20.